This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

search

Peptides & Oligonucleotides - Classic

Accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.

Partnering in the oligonucleotide and peptide therapeutics industry - WHITEPAPER

ArticleImage

Download the exclusive whitepaper

This whitepaper looks at the challenges and opportunities facing the peptide and oligonucleotide therapeutics industry in partnering, business development and commercialization strategies, using a number of case studies. The drug space is enormous and the fields of peptide and oligo development dynamic, with both technologies converging upon intracellular targets, as well as traditional extracellular ones, making the possibilities for collaboration, licensing and investment, large.

  • When to choose a CDMO?

  • Out-licencing of product manufacturing to Pharma

  • Trends in the investment and M&A landscape

  • Investment partnership case studies

  • Changing technologies impacting the investment landscape


To download simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content. Have any questions or interested in sponsoring future content? Email andrew.burrows@informa.com.

Log in or Create an Informa Connect Account to Access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.

Copyright © 2024 Informa Connect Limited. Registered in England & Wales with number 01835199, registered office 5 Howick Place, London, SW1P 1WG.